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Defects in the photoreceptor-specific gene encoding aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1)
are clinically heterogeneous and present as Leber Congenital Amaurosis, the severest formof early-onset retinal
dystrophy and milder forms of retinal dystrophies such as juvenile retinitis pigmentosa and dominant cone-rod
dystrophy. [Perrault, I., Rozet, J.M., Gerber, S., Ghazi, I., Leowski, C., Ducroq, D., Souied, E., Dufier, J.L.,
Munnich, A. and Kaplan, J. (1999) Leber congenital amaurosis.Mol. Genet. Metab., 68, 200–208.] Although not
yet fully elucidated, AIPL1 is likely to function as a specialized chaperone for rod phosphodiesterase (PDE). We
evaluatewhetherAAV-mediatedgene replacement therapy isable to improvephotoreceptor functionandsurvival
in retinal degenerationassociatedwithAIPL1defects.Weused twomousemodelsofAIPL1deficiencysimulating
three different rates of photoreceptor degeneration. TheAipl1hypomorphic (h/h)mousehas reducedAipl1 levels
and a relatively slow degeneration. Under light acceleration, the rate of degeneration in the Aipl1 h/h mouse is
increased by 2–3-fold. The Aipl12/2 mouse has no functional Aipl1 and has a very rapid retinal degeneration.
To treat the different rates of degeneration, two pseudotypes of recombinant adeno-associated virus (AAV) exhi-
biting different transduction kinetics are used for gene transfer. We demonstrate restoration of cellular function
andpreservationofphotoreceptor cells and retinal function inAipl1h/hmice followinggene replacement therapy
using an AAV2/2 vector and in the light accelerated Aipl1 h/h model and Aipl12/2 mice using an AAV2/8 vector.
We have thus established the potential of gene replacement therapy in varying rates of degeneration that reflect
the clinical spectrum of disease. This is the first gene replacement study to report long-term rescue of a photo-
receptor-specific defect and to demonstrate effective rescue of a rapid photoreceptor degeneration.
INTRODUCTION
Inherited retinal dystrophies are one of the most common causes
of blindness in the Western world, affecting approximately 1 in
3000 individuals. To date, there are no effective treatments for
this heterogeneous group of conditions that are caused by
defects in any one of over 185 different genes, 134 of which
have now been identified (www.sph.uth.tmc.edu/Retnet/). A
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majority of the defects are in genes that are expressed in either
photoreceptors or the retinal pigment epithelium (RPE). There
is considerable variation in the severity of these conditions.
The most severe are recessive conditions resulting from loss
of function; photoreceptor defects tend to result in more
severe disease than that caused by RPE defects. This is exem-
plified by Leber Congenital Amaurosis (LCA), a genetically
heterogeneous, autosomal recessive retinal degenerative
disease which is the most severe form of inherited retinopathy
and the commonest cause of congenital blindness in children
accounting for 10–18% of cases (1,2). LCA is characterized
by markedly impaired vision or complete blindness and near
absence of electrical responses to light within the first year
of life.
Over the past two decades, major advances in understanding
disease processes in animal models of human retinopathy and
the development of efficient retinal gene transfer using either
adeno-associated virus (AAV) or lentivirus-based vector
systems have led to robust proof of concept studies of gene
replacement therapy (3–8). Better outcomes have generally
been seen in models of RPE defects (6,9–11) probably due
to the fact that gene delivery to RPE cells is more efficient
and widespread and more importantly, the photoreceptor
cells in these conditions are inherently healthy. The culmina-
tion of these developments is the commencement of three
human ocular gene therapy trials, treating patients with
LCA, caused by mutations in an RPE-specific gene, RPE65
(12–14). Although the patients involved in these trials were
predominantly adults and have established retinal degener-
ation, the preliminary results suggest some improvement in
visual function is possible (12,13), paving the way for
additional clinical trials of gene therapy for a variety of inher-
ited retinal degenerations.
In general, gene replacement therapy for photoreceptor-
specific defects has not been very effective at slowing severe
photoreceptor degeneration characterized by fast progression,
such as the rd1 mice. AAV-based vectors have been shown
to be the most efficient vectors for gene transfer to the
retina (15,16). A number of AAV serotypes are able to trans-
duce photoreceptors efficiently although AAV2/5 and particu-
larly AAV2/8 appear to be the most efficient (17). The first
studies using an AAV2/2 vector in rds mice did not alter
rate of retinal degeneration despite the restoration of structure
and function—50% of the photoreceptors are still lost by 8
weeks (3,18). More success was achieved in RPGRIP deficient
mice following AAV2/2-mediated gene replacement therapy
(7). This is possibly due to a requirement for lower levels of
transgene expression in RPGRIP deficient mice or because
the structural abnormality in rds mice was too severe to
correct effectively. The speed of disease progression is
likely to be important in determining the potential for success-
ful therapy. The window of opportunity in a disease model is
created by the balance between time for vector-mediated
expression and rate of photoreceptor degeneration. In models
of rapid degeneration such as the rd1 mouse, gene replacement
therapy using AAV2/2 vectors is rather unlikely to be success-
ful since most of the photoreceptors are lost before maximal
transgene expression can take place. The rd1 mouse is a well-
characterized model of autosomal recessive retinitis pigmen-
tosa and has a very fast retinal degeneration. It is homozygous
for a null mutation in the Pde6b gene encoding the ß-subunit
of rod photoreceptor cGMP phosphodiesterase which results in
the loss of function of ß-PDE. Photoreceptor degeneration
begins at P10 and is complete by 4 weeks. Despite a
number of attempts to treat the rd1 mice by gene replacement
therapy using a variety of vectors (19–22), effective rescue
has proved elusive. However, gene replacement therapy has
been more effective in rd10 mice, a hypomorphic Pde6b
mutant with a missense mutation in exon 13. The mutation
causes partial loss of PDE activity and a milder phenotype
than the mutation in rd1 mice. Loss of photoreceptor cells
begins at P16 and is complete by P60. Dark rearing slows
the degeneration by a further 4 weeks and allows the for-
mation of outer segments that are not normally formed in
either rd10 or rd1 mice. Pang et al. (23) showed it was poss-
ible to preserve photoreceptors and retinal function following
gene replacement therapy using an AAV2/5 vector. However,
animals were dark reared until vector administration at P14
and then dark reared for a further 2 weeks after treatment.
They were then exposed to light for 1 week before the effect
of treatment was assessed.
The human aryl hydrocarbon receptor-interacting protein-
like 1 (AIPL1) gene encodes a 384 amino acid protein that
incorporates three consecutive tetratricopeptide repeat motifs
and shares close structural homology with the FK506-binding
protein family of specialized chaperones (24). These features
collectively suggest a role for AIPL1 as a molecular chaperone
involved in retinal protein folding or cellular translocation
(25,26). In patients, AIPL1 defects are associated with LCA
as well as with cone-rod dystrophy and juvenile retinitis pig-
mentosa (27,28). We have used two mouse models of AIPL1
deficiency. One model, the Aipl12/2 mouse has a targeted
disruption of the Aipl1 gene and produces no Aipl1 (29).
The second model, the Aipl1 h/h mouse, has a targeted disrup-
tion of intron 2 that results in reduced levels of Aipl1 mRNA
and a 20–25% reduction in the levels of Aipl1 (30). Pathogen-
esis of AIPL1-associated retinal degeneration has been linked
to cGMP PDE. In parallel to AIPL1 deficiency, all three sub-
units of the cGMP-PDE holoenzyme (a, ß and g) were found
to be reduced post-transcriptionally in both mouse models,
suggesting that AIPL1 may have a role in the post-
translational processing of cGMP-PDE. With complete loss
of photoreceptors by 3 weeks, the retinal degeneration in the
Aipl12/2 mouse is even faster than rd1 mouse. Photo-
receptor loss is considerably slower in the Aipl1 h/h hypo-
morphic mutant. Retinal degeneration begins after 12 weeks
of age and by 6–8 months over half of photoreceptor cells
are lost. Constant light exposure further accelerates the
degeneration in the Aipl1 h/h mouse so that photoreceptor
cell loss is almost complete by 5 months of age. In these
models, normal retinal histology and photoreceptor mor-
phology including outer segments are present at birth and
most of photoreceptor cells are lost after the retina has termin-
ally differentiated.
The aim of this study is to develop an effective gene therapy
strategy to treat retinal dystrophies due to AIPL1 deficiency.
Given the variable severity of disease seen in patients with
AIPL1 defects, we assess the efficacy of gene replacement
therapy using AAV2/2 and AAV2/8 vectors to treat
Aipl12/2 and Aipl1 h/h mice that simulate different rates
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of retinal degeneration. We assess the effect of gene transfer
using light and electron microscopy, immunohistochemistry
and by electroretinography. This study is the first to describe
long-term rescue of a photoreceptor-specific defect following
gene replacement therapy. It also the first to describe the use
of an AAV2/8 vector to treat a retinal degeneration and
demonstrate effective rescue of a rapid photoreceptor
degeneration.
RESULTS
Verification of Aipl1 transgene expression
The murine Aipl1 cDNA was PCR amplified from murine
retinal cDNA and cloned between into an AAV2 plasmid
backbone with a CMV promoter and SV40 polyadenylation
site. The plasmid construct pD10/CMV-Aipl1 and the viral
vector AAV2-CMV-Aipl1 were tested in vitro to ensure that
they were functional. Transfection using the plasmid construct
and transduction using a recombinant AAV serotype 2 vector,
AAV2-CMV-Aipl1, were performed in 293T cells. Western
blot analysis showed a single, appropriate band of 38 kDa
(Fig. 1A). We proceeded to test the function of the viral
vector in the Aipl1 h/h mouse model. Messenger RNA was
isolated from Aipl1 h/h retinas 28 weeks after unilateral sub-
retinal injection of AAV2-CMV-Aipl1 into three animals.
Quantitative PCR and paired analysis of the samples showed
that the mean relative level of Aipl1 expression was more
than nine times higher than in untreated eyes, although it
should be noted that this difference might in part be due to
an increased loss of photoreceptor cells in the untreated
eyes. The mean relative level in treated eyes at 28 weeks post-
injection was approximately half that seen in wild-type
animals (data not shown).
AAV-mediated Aipl1 gene replacement therapy results in
increased levels of PDE and restores localization to the
outer segment
AAV2-CMV-Aipl1 was injected subretinally into the superior
and inferior hemispheres of the right eyes of 4-week-old Aipl1
h/h animals (n ¼ 16), leaving the contralateral left eye
untreated to serve as an internal control for inter-animal vari-
ation and test-retest variability. As additional controls, a
number of Aipl1 h/h mice (n ¼ 5) received subretinal injec-
tions of PBS and wild-type C57B/6 (n ¼ 6) received subretinal
injections of AAV2-CMV-Aipl1. Retinas were analysed at 28
weeks after injection (Fig. 1B). In wild-type mice, Aipl1 was
Figure 1. Verification of Aipl1 expression. (A) Western blotting of 293T cells transfected with the plasmid construct and transduced by recombinant vector,
AAV2-CMV-Aipl1 produces a 38 kDa protein band corresponding to Aipl1 protein. (B) Aipl1 immunofluorescence (green) is reduced in untreated Aipl1
h/h retina compared with treated retina which shows strong immunofluorescence localized mainly to the inner segments (IS) similar to that seen in wild-type
retina. (C–E) Confocal images of double immunofluorescent microscopy for ß-PDE and Aipl1. In untreated retina, ß-PDE immunofluorescence (red) colocalizes
with Aipl1 immunofluorescence (green) in the photoreceptor IS. Following subretinal injection of AAV2-CMV-Aipl1, ß-PDE immunofluorescence is translo-
cated to the outer segments (OS) in the treated retina. Hence in treated retina, Aipl1 immunofluorescence in the IS is separate from ß-PDE immunofluorescence
in the OS, which is similar to that found in wild-type retina. Cell nuclei are counterstained with Hoechst dye 33342 (blue). INL, inner nuclear layer; ONL, outer
nuclear layer.
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found mainly in photoreceptor inner segments, but some
protein was present in the cell body and synaptic spherules.
In uninjected or mock (PBS)-injected Aipl1 h/h retinas,
Aipl1 immunofluorescence was much reduced and there was
marked thinning of the outer and inner nuclear layers and dis-
ruption of the retinal architecture. Following injection of
AAV2-CMV-Aipl1, there was a substantial increase in Aipl1
immunofluorescence in appropriate cellular locations. Immu-
nofluorescence was also seen in the RPE layer because
AAV2 transduces both photoreceptor cells and RPE and a ubi-
quitous promoter was used to drive transgene expression.
Since it had previously been suggested that Aipl1 affected
rod phosphodiesterase (PDE) levels (29,30), we investigated
the effect of rAAV-mediated Aipl1 gene replacement on rod
PDE expression and localization in photoreceptors 28 weeks
after vector administration (Fig. 1C–E). Confocal imaging
of Aipl1 and b-PDE immunofluorescence in untreated Aipl1
h/h retinas revealed not only reduced Aipl1 immunofluores-
cence but also reduced levels of b-PDE which was localized
to the inner segments rather than outer segments (Fig. 1C).
In eyes that received subretinal AAV2-CMV-Aipl1, substan-
tially increased Aipl1 immunofluorescence was accompanied
by increased immunofluorescence for ß-PDE. More interest-
ingly, a shift in the subcellular localization of b-PDE was
seen in treated retinas; ß-PDE immunostaining was restored
to the outer segments of photoreceptors (Fig. 1D). The relative
amount and localization of Aipl1 and PDE in treated eyes
were similar to that seen in wild-type sections (Fig. 1E).
These results indicated that not only the amount of PDE but
also its subcellular localization is dependent on Aipl1.
Maintenance of photoreceptor function in Aipl1 h/h mice
following AAV-mediated gene replacement therapy
To evaluate the effect of AAV-mediated Aipl1 expression on
retinal function, dark-adapted, scotopic ERG recordings were
obtained from 16 Aipl1 h/h animals at regular intervals follow-
ing subretinal injection of AAV2-CMV-Aipl1 when the
animals were 4 weeks old. ERGs were recorded simul-
taneously from the treated and untreated eyes of each
animal. Representative ERG recordings from a single Aipl1
h/h mouse at 20 weeks post-injection (Fig. 2A) and ERG
waveforms at 28 weeks post-injection (Fig.2B) showed that
ERG amplitudes in the treated eye were substantially higher
compared with the untreated fellow eye. Oscillatory potentials,
which represent post-synaptic neuronal activity in the inner
retina, were more obvious in the treated eye, but were
reduced in the untreated eye. A series of ERG recordings
obtained from the treated and untreated eyes of another
Aipl1 h/h animal at various follow-up time points following
subretinal injection of AAV2-CMV-Aipl1 is shown in
Figure 2C. Over the 28 week period, the untreated eye
showed a steady decline in a-wave and b-wave amplitude,
whereas the treated eye showed stabilization of amplitude
and waveform with differences apparent from 12 weeks post-
injection onwards (Fig. 2C). At 28 weeks, the ERG response
from the untreated eye was almost flat, whereas the treated
eye maintained a substantial ERG response, indicating preser-
vation of photoreceptor function.
At each time point assessed, there was considerable vari-
ation in the ERG amplitudes in the untreated eyes of individ-
ual Aipl1 h/h mice, indicating inter-animal variation in the rate
of photoreceptor cell degeneration in this model (data not
shown). Furthermore, the ERG results of the same cohorts
of animals vary substantially between recording sessions,
suggesting high inter-session variability. In view of this vari-
ation, paired t-tests were used to analyse the mean b-wave
and a-wave amplitudes between treated and untreated eyes
at the various time points from 4 to 28 weeks (Fig. 2D and
E). Both the b-wave and a-wave amplitudes were significantly
higher in the treated compared with the untreated eyes at 20,
24 and 28 weeks post-injection (P  0.05). There was an
initial increase in ERG amplitudes from birth until adulthood
(8 weeks) that reflected normal development in mice. Four
weeks after vector administration, there was a reduction in
b-wave amplitudes in treated eyes that was probably due to
injection-related trauma. However, from 20 weeks post-
injection onwards, b-wave amplitudes were significantly
higher in treated compared with untreated eyes (P  0.05), a
difference which remained consistent up to the final time
point of 28 weeks post-injection. The mean b-wave amplitude
in treated eyes (n ¼ 15; mean ¼ 295.3+ 13.6 mV) at 20
weeks post-injection was 20% higher that in untreated
eyes (n ¼ 15, mean ¼ 243.6+ 15.6 mV). Analysis of mean
a-wave amplitudes similarly showed that treated eyes main-
tained higher amplitudes compared with untreated eyes, this
difference was statistically significant (P  0.05) from 20
weeks post-injection onwards up to the final time point of
28 weeks post-injection (Fig. 2E). At 20 weeks post-injection,
the mean a-wave amplitude in treated eyes (n ¼ 15; mean ¼
109.6+ 20.4 mV) was 38% higher than that in untreated
eyes (n ¼ 15; mean ¼ 79.2+ 33.8 mV).
In the group of PBS-injected animals, no significant differ-
ences were seen in the b-wave amplitudes between injected
and uninjected eyes (Supplementary Material, Fig. S1). No
significant differences were found in the b-wave amplitudes
in treated and untreated eyes of wild-type C57B/6 mice
which received a unilateral subretinal injection of
AAV2-CMV-Aipl1, indicating that over expression of Aipl1
in photoreceptors and RPE did not affect retinal function (Sup-
plementary Material, Fig. S2A).
AAV-mediated gene replacement therapy increases
photoreceptor survival in Aipl1 h/h mice
The effects of AAV-mediated Aipl1 expression in the same
group of Aipl1 h/h mice were evaluated by assessing the
retinal morphology. Semi-thin sections of treated and
untreated Aipl1 h/h retinas were taken at 52 weeks after unilat-
eral injection of AAV2-CMV-Aipl1. Treated eyes had
received double subretinal injections of the therapeutic
vector in the superior and inferior hemisphere of the eye.
Prior to embedding, the eyes were orientated so that sections
would be sagittally orientated to show the superior and inferior
treated areas of the retina. In treated eyes, the retina had con-
siderably more photoreceptor cell nuclei and the photoreceptor
outer segments were longer and more densely packed
(Fig. 3A). The preservation of photoreceptor cells was
evident throughout the treated retina as seen by the preser-
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vation of the outer nuclear layer around the whole of the sagit-
tal section. Untreated retinas showed substantial loss of photo-
receptor cell nuclei and outer segments and this was also seen
as a thinning of the outer nuclear layer throughout the sagittal
section of the eye (Fig. 3A). Ultrastructurally, differences
were seen in morphology of photoreceptor outer segments.
The number of photoreceptor outer segments (OS) in untreated
Aipl1 h/h retina was substantially reduced, markedly shortened
and disorganized. The OS disk membranes were also disorga-
nized and less tightly packed and there was loss of the normal
laminar arrangement (Fig. 3B). Vacuolar inclusions containing
debris material was present in the inner segments of the retina
(Fig. 3C). The contact between the RPE and photoreceptor OS
was also abnormal and reduced. Intervening vacuoles could also
be seen between OS tips and the RPE. In contrast, in treated
Aipl1 h/h retina, photoreceptor OS were elongated and the
membranous OS disks had a regular and densely packed
arrangement (Fig. 3D), which was similar to that seen in wild-
type mice (Fig. 3E). The photoreceptor OS in treated retina
maintained close contact with the RPE and showed normal
interdigitation with the microvilli of the RPE (Fig. 3F).
Morphometric analysis of treated and untreated eyes of
Aipl1 h/h mice at 28 weeks post-injection (Fig. 3G) showed
that the mean number of photoreceptor cell nuclei in treated
eyes (n ¼ 7) was found to be 41% higher than in the
untreated eyes (mean photoreceptor cell count in treated
Figure 2. Functional rescue assessed by ERG analysis following subretinal injection of AAV2-CMV-Aipl1. (A) ERG intensity series at 20 weeks following
treatment. ERG traces shown in each chart were recorded at intensities of 0.1, 1, 10, 100, 1000 and 3000 mcds/m2. The treated eye maintains substantially
larger amplitudes and oscillatory potentials while in the untreated eye, there is loss of amplitude even at higher flash intensities. (B) Representative ERG wave-
forms at 28 weeks post-injection from treated and untreated Aipl1 h/h eyes. A wild-type waveform is shown for comparison. The treated eye shows a discernible
a-wave and a higher b-wave compared with the untreated eye. (C) A time course series of ERG recordings at the light intensity of 1000 mcds/m2 from a single
Aipl1 h/h mouse taken at the various time points is shown. ERG amplitudes from the untreated eye diminish with time, whereas ERG responses are maintained in
the treated eye. (D) Mean ERG b-wave amplitudes at flash intensity of 1000 mcds/m2 from treated eyes were significantly higher than untreated eyes from 20
weeks post-injection onwards (P  0.05). (E) Mean ERG a-wave amplitudes at flash intensity of 1000 mcds/m2 from treated and untreated eyes show that the
differences were statistically significant from 20 weeks post-injection onwards (P  0.05). Error bars, +SEM.
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eyes ¼ 479.3+ 16.6 versus untreated eyes ¼ 339.3+ 8.2;
P ¼ 0.0003) (Fig. 3H). The preservation of photoreceptors in
treated eyes was consistent in all of the seven animals
assessed, with a significantly greater photoreceptor nuclei
count in the treated eye compared with the fellow untreated
eye (P , 0.05) (Fig. 3I).
The outer nuclear layer was quantified in five wild-type
C57B/6 mice that received unilateral subretinal injection of
AAV2-CMV-Aipl1 using the same method. Supplementary
Material, figure S2B shows confocal images of an injected
and uninjected eye from a single wild-type animal. Paired
t-test showed no significant differences between the mean
photoreceptor cell count of wild-type eyes that received subret-
inal injection of AAV2-CMV-Aipl1 and uninjected eyes (Sup-
plementary Material, Fig. S2C), indicating that there was no
detrimental effects on histology or photoreceptor survival.
Figure 3. Morphologic analysis of treated and untreated Aipl1 h/h retina. (A) Semithin light micrographs of treated and untreated Aipl1 h/h retina 52 weeks after
injection with AAV-CMV- Aipl1. Higher magnification images from the retinas are shown in the centre. The outer nuclear layer (ONL) in the treated retina is
substantially thicker and the photoreceptor outer segments (OS) are longer and more densely packed, whereas in the untreated retina, there is loss of outer nuclear
layer and outer segments. The sagittal sections show that the preservation of photoreceptors is uniformly present throughout the superior and inferior hemispheres
of the treated eye which were the sites of the injections. (B–F) Electron microscopy (EM) of the same tissue samples. Outer segments in untreated retina are
markedly shortened and contain disorganized disks which form whorls instead of stacks (B). There are very few outer segments and multiple debris-filled vacu-
oles (de) in the retina (C). The treated retina (D) shows long outer segments (OS) with well-organized outer segment disks, resembling those of wild-type retina
(E). Outer segments in treated retina are numerous and interdigitate normally with RPE microvilli (MV) (F). IS, inner segments; PR, photoreceptor nuclei.
(G) Quantitative analysis of the ONL using confocal microscopy shows visibly thicker ONL in treated eyes compared with untreated eyes at 28 weeks post-
injection. (H) Paired t-test showed that the mean ONL cell count of treated eyes was significantly higher than untreated eyes (P ¼ 0.0003, n ¼ 7). This was
consistent in every animal that were assessed (I). Error bars, +SEM.
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AAV-mediated gene replacement therapy using a human
cDNA results in effective treatment of Aipl1 h/h mice
In order to evaluate a therapeutic construct that might be used
in clinical studies, we substituted the mouse Aipl1 cDNA
within the expression cassette with a human AIPL1 cDNA.
Aipl1 h/h mice (n ¼ 10) received subretinal injections of
AAV2-CMV-AIPL1 when they were 4 weeks old and were
analysed as before using morphological assessments and
ERG recording. Follow up, however, included longer time
points, up to 50 weeks post-injection (Fig. 4A–C). Paired
analysis of photoreceptor cell counts between treated and
untreated eyes showed that treated eyes had significantly
higher (73% higher) photoreceptor cell count than untreated
eyes at 50 weeks post-injection (mean photoreceptor cell
count in treated eyes¼463.5+ 19.8 versus untreated eyes ¼
267.4+ 13.9, P ¼ 0.00006, n ¼ 6) (Fig. 4A and B). Treated
eyes that received subretinal injection of AAV-CMV-AIPL1
maintained significantly higher b-wave ERG amplitudes up
to 50 weeks post-injection (P ¼ 0.03) (Fig. 4C). At the final
time point of 50 weeks, the mean b-wave amplitude in
treated eyes (n ¼ 10, mean ¼ 194.6+ 25.2 mV) was 57%
higher than the mean b-wave amplitude in untreated eyes
(n ¼ 10, 123.98+ 20.42 mV). AAV-CMV-AIPL1 treated
eyes showed significantly higher a-wave amplitudes than
untreated eyes between 16 and 50 weeks post-injection (P ,
0.05) (Fig. 4D).
AAV2/8 mediated gene replacement therapy using a
murine cDNA results in effective rescue of
light-accelerated retinal degeneration in Aipl1 h/h mice
In order to assess the efficacy of gene replacement therapy in the
context of a more rapid degeneration, we accelerated the photo-
receptor cell loss in Aipl1 h/h mice by exposing animals to con-
tinuous light. We had previously found that Aipl1 h/h mice kept
under constant light exhibited a much faster course of degener-
ation (our unpublished observation). To ensure that we obtained
more rapid onset of gene expression from the AAV vector, we
produced AAV2/8-CMV-Aipl1 by packaging the therapeutic
construct using AAV8 capsid. A group of Aipl1 h/h mice
(n ¼ 23) received unilateral subretinal injections of AAV2/
8-CMV-Aipl1 when they were 4 weeks old. The mice were
placed under constant illumination 1 week after the subretinal
injections. Although the retinal degeneration progressed at a
faster rate, photoreceptor rescue was still obtained. When the
group of AAV2/8-treated Aipl1 h/h mice that underwent light
acceleration was compared with the AAV2/2-CMV-Aipl1
treated mice, Aipl1 h/h mice that did not undergo constant
Figure 4. Photoreceptor cell rescue by AAV2/2-mediated expression of human AIPL1 in Aipl1 h/h retina. (A) Confocal microscopy at 40 weeks post-injection
showed visibly thicker outer nuclear layer (ONL) in treated eyes compared with untreated eyes. (B) Mean ONL cell counts in treated eyes were significantly
higher than untreated eyes (P ¼ 0.00006). (C) Statistical analysis using paired t-test showed that ERG b-wave amplitudes in treated eyes were significantly
higher compared with untreated eyes at time points of 16, 20, 28, 36 and 50 weeks post-injection (P, 0.05). (D) AAV-CMV-AIPL1 treated eyes showed sig-
nificantly higher a-wave amplitudes than untreated eyes between 16 and 50 weeks post-injection (P , 0.05). Error bars, +SEM.
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light exposure, larger differences between treated and untreated
eyes in terms of functional and morphological outcome
measures (Figs 5 and 6) were obtained in the light exposed
animals. ERGs were recorded simultaneously from the treated
and untreated eyes of each animal. Figure 5A shows a light
intensity series at 21 weeks post-injections. At this stage, the
Figure 5. Functional improvement following AAV2/8-mediated Aipl1 expression. (A) ERG intensity series from an Aipl1 h/h mouse at 21 weeks post-injection
under constant light conditions. ERG was recorded flash intensities of 0.1, 1, 10, 100, 1000 and 3000 mcds/m2. At this time, the treated eye maintains substantial
ERG amplitudes whereas the untreated eye shows no discernible ERG response. (B) Representative ERG waveforms from a single Aipl1 h/h mouse at 21 weeks
following subretinal injection of AAV2/8-CMV-Aipl1 and constant light acceleration. (C) Representative ERG recordings from a single animal at various time
points showing maintenance of ERG amplitudes in treated eye but not in untreated eye. (D) Mean ERG b-wave amplitudes at flash intensity of 1000 scotopic
mcds/m2 from treated eyes were significantly higher than untreated eyes from 9 weeks post-injection onwards (P, 0.05). Error bars, +SEM. (E) Mean ERG
a-wave amplitudes at flash intensity of 1000 scotopic mcds/m2 from treated eyes were also significantly higher compared with untreated eyes from 5 weeks
post-injection onwards (P, 0.05). Error bars, +SEM.
Figure 6. Structural preservation following AAV2/8-mediated Aipl1 expression. (A) Confocal images of the treated and untreated retina from a single Aipl1 h/h
mouse at 21 weeks following subretinal injection of AAV2/8-CMV-Aipl1. (B) Comparison of the mean ONL cell count (n ¼ 7) shows a 123% increase of photo-
receptor nuclei in treated eyes compared with untreated eyes (P ¼ 0.0007). (C) A statistically significant higher ONL count was obtained in the treated eye
compared with the untreated eye (P , 0.005) in each animal that was assessed. (D) Semithin light micrographs of treated and untreated Aipl1 h/h retina
from a single animal 21 weeks after injection with AAV2/8-CMV-Aipl1. Preservation of the ONL is evident throughout the treated retina. Higher magnification
image shows several rows of photoreceptor nuclei and visible outer segments (OS). The untreated eye has complete loss of ONL and the INL lies adjacent to the
RPE layer. (E–H) EM of the same tissue samples. Photoreceptor outer segments (OS) are present in the treated retina although shortened with some disorgan-
ization of the membranous disks (E), and the OS tips appear to invaginate the microvilli (MV) of the RPE. Photoreceptor cells (PR) and OS are numerous with
metabolically active inner segments (IS) containing numerous mitochondria (F). The untreated retina shows complete absence of outer segments with debris-
filled vacuolar inclusions (de) (G). There is complete loss of photoreceptor cells, only the INL remains lying adjacent to the RPE (H). (I) Western blot of retina
homogenates from three animals showing increased b-PDE in the treated eye. b-actin was used as loading control. (J) Quantification of b-PDE from the three
pairs of samples shown as mean+SEM and plotted as percentage of the wild-type control. Levels of b-PDE in treated eyes were 66% of wild-type, whereas
untreated eyes had 9% of wild-type levels (P ¼ 0.02 treated versus untreated).
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treated eye maintains substantial ERG amplitudes and shows
increasing responses elicited by the increasing light stimuli,
while ERG responses are lost in the untreated eye. Normally
shaped waveforms, similar to that of wild-type mice, were
recorded from treated eyes while from untreated eyes, the
ERG was virtually undetectable (Fig. 5B). ERGs recorded at
the various follow-up time points from a single procedure
animal in this group are shown in Figure 5C. Over time, the
ERG amplitudes in the untreated eye decreased rapidly and dis-
appeared completely by 21 weeks, while the ERG response in
the treated eye was maintained throughout the follow-up
period, suggesting that photoreceptor survival was prolonged
following treatment with AAV2/8-CMV-Aipl1. The apparent
improvement in the ERG amplitudes between weeks 5 and 14
was likely to be due to variation occurring between recording
sessions. Paired statistical analysis of the mean ERG b-wave
amplitudes showed that b-wave amplitudes in treated eyes
were significantly higher than untreated eyes up to 21 weeks
post-injection (Fig. 5D). At 21 weeks post-injection, the mean
b-wave amplitude in treated eyes (n ¼ 20; mean ¼ 87.3+
5.4 mV) was 110% higher that in untreated eyes (n ¼ 20,
mean ¼ 41.5+ 4.2 mV). Analysis of the mean ERG a-waves
showed that treated eyes also had significantly higher a-wave
amplitudes compared with untreated eyes (Fig. 5E). Statisti-
cally significant differences were seen at earlier time points
from 5 weeks post-injection onwards up to the last time point
of 21 weeks post-injection. At 21 weeks post-injection, mean
ERG a-wave in treated eyes was 16.8+ 2.3 mV (n ¼ 20) and
in untreated eyes it was 8.9+ 2.8 mV (n ¼ 20).
There were many more photoreceptor cells in treated eyes
compared with untreated controls (Fig. 6A). The mean
number of photoreceptor nuclei in treated eyes (n ¼ 7) was
123% higher than in untreated eyes (mean photoreceptor cell
count in treated eyes¼202.1+ 20.2 versus untreated eyes ¼
90.64+ 23.0; P ¼ 0.0007) at 21 weeks post-injection
(Fig. 6B). In each individual animal that was assessed, signifi-
cant photoreceptor preservation was seen in the treated eye
compared with contralateral control (Fig. 6C). In order to
assess the extent of photoreceptor preservation, we analysed
sagittally orientated semithin retinal sections and found ONL
preservation throughout the whole of the eye (Fig. 6D), indi-
cating that the effect of treatment was not localized. Untreated
eyes showed complete loss of the ONL by 21 weeks. Electron
microscopy of AAV2/8-CMV-Aipl1 treated eyes showed that
although outer segments were present, these were shortened
compared with animals which did not undergo light exposure
and the membranous disks were less well organized (Fig. 6E).
Photoreceptor inner segments appeared to be normal in
appearance (Fig. 6F). In untreated eyes, no photoreceptor
cells could be seen (Fig. 6G); the inner nuclear layer and
bipolar cells were seen to lie adjacent to the RPE, with inter-
vening vacuoles or debris-containing spaces (de) (Fig. 6H).
To investigate the effect of AAV8-mediated Aipl1
expression on PDE levels, retinal homogenates of treated
and untreated eyes were obtained from the AAV2/
8-CMV-Aipl1 injected Aipl1 h/h mice at 21 weeks after treat-
ment. Western blot analysis of paired retinal homogenates
from treated Aipl1 h/h mice and wild-type controls showed
that PDE was present in treated mutant eyes and severely
reduced or absent from untreated eyes (Fig. 6I). Quantification
of the immunoblots indicated that PDE levels in treated eyes
were significantly higher than in untreated eyes (P ¼ 0.02).
At 21 weeks post-injection with light acceleration, the mean
level of PDE in treated eyes was 65% of wild-type levels
while in untreated eyes, PDE was 10% of wild-type
(Fig. 6J). Since treated eyes at this time point contained
approximately half the normal number of photoreceptor
cells, following Aipl1 gene replacement therapy, the level of
PDE in each cell might be similar to that in wild-type photo-
receptors if we adjust for the number of cells.
Effective rescue of Aipl12/2 mice following AAV2/
8-mediated gene replacement therapy
Since an AAV2/8 vector proved effective for mediating gene
replacement therapy in the light accelerated Aipl1 h/h
model, we proceeded to evaluate the efficacy of AAV2/
8-CMV-Aipl1 mediated gene replacement therapy in the
Aipl12/2 mouse model that had an extremely fast degener-
ation. A group of Aipl12/2 mice (n ¼ 12) received unilateral
subretinal injections of AAV8-CMV-Aipl1. Because of the
early onset of the degeneration, we treated animals when
they were 12 days old (P12). Assessments of retinal function
and immunohistochemistry were performed 16 days post-
injection when the mice were 28 days old (Fig. 7). In untreated
Aipl12/2 mice, the ONL was completely absent, but in
treated mice we observed a thick ONL with inner segments
containing Aipl1 and outer segments containing PDE. In
untreated eyes, no Aipl1 or PDE immunofluorescence was
observed. Semithin sections of retina from 4-week-old mice
showed that the treatment resulted in substantial preservation
photoreceptor cells with long, densely packed outer segments
(Fig. 7B). In contrast, no photoreceptor cells could be seen in
untreated eyes. ERG recordings were normally extinguished
by P18 in the Aipl12/2 mouse. While untreated eyes had
flat ERG tracings, treated Aipl12/2 eyes exhibited good sco-
topic and photopic ERG amplitudes 16 days after treatment
(Fig. 7C). The difference in mean scotopic ERG b-wave
amplitudes between treated and untreated eyes was statisti-
cally significant (P ¼ 0.03; mean b-wave treated ¼ 243.5+
67.2 mV, mean b-wave untreated ¼ 6.25+ 8.9 mV, n ¼ 4).
At 6 weeks post-injection, treated eyes maintained signifi-
cantly higher ERG b-wave amplitude compared with untreated
eyes (P ¼ 0.0006; mean b-wave treated ¼ 234.7+ 51.1 mV,
mean b-wave untreated ¼ 25.5+ 6.4 mV, n ¼ 6). These find-
ings indicated that early treatment using AAV8-CMV-Aipl1
was able to significantly improve photoreceptor function and
delay retinal degeneration in the Aipl12/2 mouse. ERG
analysis of Aipl12/2 mice injected with AAV2/2 therapeutic
vector did not show any evidence of preservation function or
photoreceptor rescue (Fig. 7D). These mice were also injected
at P12 and neither the treated nor the untreated eyes showed
any ERG responses at P28 (16 days post-injection).
DISCUSSION
In this study, we have shown that AIPL1-associated retinal
degeneration is amenable to gene replacement therapy. We
have demonstrated efficacy in animal models of AIPL1
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deficiency that exhibit three different rates of degeneration.
We demonstrate efficacy first in the hypomorphic Aipl1 h/h
model and then in increasingly rapid degenerations, specifi-
cally the light accelerated Aipl1 h/h model and the
Aipl12/2 model. This study demonstrates the effective long-
term rescue of a photoreceptor-specific defect and the most
effective rescue to date of a rapid retinal degeneration.
In general, gene-based treatments for autosomal recessive
retinal dystrophies require not only restoration of function to
affected cells but also the prevention of photoreceptor cell
death. In this study, we demonstrate that we are able to
correct the cellular defect. Following subretinal delivery of
Aipl1 replacement genes packaged in either AAV2 or AAV8
vectors, there is increased production of Aipl1 in photo-
receptor inner segments and this led to increased levels of
PDE and the restoration of normal PDE translocation from
the inner to the outer segments. As a result, retinal degener-
ation is significantly slowed. We observe improved photo-
receptor cell survival, preservation of outer segment
morphology and stabilization of retinal function. Both thera-
peutic constructs, one containing the murine Aipl1 cDNA
and the other containing the human AIPL1 cDNA are similarly
effective. This is not surprising since AIPL1 is highly con-
served between species; there is 96% similarity and 86% iden-
tity between the murine and human cDNAs.
AAV-mediated gene replacement therapy results in a sig-
nificant preservation of photoreceptors and retinal function
in Aipl1 h/h mice 1 year after treatment—the latest time
point examined. This is the most sustained rescue of a
photoreceptor-specific gene defect reported to date. The
most sustained rescue reported previously was following
AAV-mediated gene replacement therapy in an RPGRIP
deficient mouse model, in which photoreceptors were pre-
served for 5 months (7). Photoreceptors are still present in
untreated Aipl1 h/h mice that are 12 months old and the dur-
ation of rescue probably reflects the mild phenotype and
slow rate of degeneration. Retinal degeneration is more
severe in Aipl1 h/h mice kept under constant light, with loss
of 84% of photoreceptors by 5 months. This can be attributed
to a heightened sensitivity of the Aipl1 h/h mice to light
stimuli, as WT mice kept under identical conditions show no
light damage at all. Despite the more rapid cell loss, we still
observe very significant preservation of photoreceptor cells
and retinal function 5 months after gene replacement therapy
using an AAV2/8. While rearing animals in continuous light
accelerates photoreceptor loss in Aipl1 h/h mice, even faster
retinal degeneration occurs in Aipl12/2 mice with all photo-
receptors lost by the time animals are 3 weeks old. Following
AAV2/8 mediated gene replacement therapy in Aipl12/2
mice, we have been able to achieve significant preservation
of photoreceptor and retinal function for over 3 months, the
last time point tested so far. This represents the most effective
rescue to date of a rapid retinal degeneration.
AAV-mediated gene replacement therapy does not comple-
tely prevent loss of photoreceptor cells. At 50 weeks,
AAV2-CMV-AIPL1 treated eyes from Aipl1 h/h mice has on
average 15% fewer photoreceptor cells than normal wild-
type mice, while untreated eyes has 50% fewer photo-
receptor cells. Although gene replacement therapy in
Aipl12/2 mice using AAV2/8 is remarkably effective, at 8
weeks after vector administration, treated eyes contain
10% fewer photoreceptors than wild-type eyes (data not
shown). There may be several reasons why photoreceptor
degeneration proceeds despite treatment. First, only two-thirds
Figure 7. Rescue of the Aipl12/2 mouse following subretinal injection of
AAV8-CMV-Aipl1. (A) The untreated eye at 16 days post-injection shows no
Aipl1 or b-PDE on immunostaining. Treated eye shows strong murine Aipl1
immunofluorescence (green) in the inner segments and b-PDE immunofluores-
cence (red) in the outer segments. (B) Semithin sections at 19 days post-
injection from a procedured Aipl12/2 mouse. The ONL is absent in the
untreated retina. The treated retina show preservation of photoreceptor outer
segments (OS) and six to seven rows of photoreceptor nuclei in the outer
nuclear layer (ONL). (C) Representative dark and light adapted ERG wave-
forms from the untreated and treated eyes of single Aipl1 h/h mouse at 16
days post-injection. The ERG is extinguished in the untreated eye while there
is a good b-wave amplitude from the treated eye. An ERG tracing from a wild-
type mouse is shown for comparison. (D) ERG recordings fromAipl12/2mice
injected with the AAV2/2 therapeutic vector did not show any ERG responses
from the treated and untreated eyes at 16 days post-injection.
Human Molecular Genetics, 2009, Vol. 18, No. 12 2109
 at U
CL Library Services on N
ovem
ber 15, 2013
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
of the retina (at most) has been transduced. Secondly, even
earlier intervention than postnatal day 12 might be necessary
for maximal therapeutic effect. In this regard, it is noted that
AAV8 could take 3–4 days to turn on the expression of the
therapeutic gene. By then, mice will be over 15 days of age
when substantial cell loss is known to have occurred.
Thirdly, expression level from the CMV promoter might not
have been optimal for AIPL1.
In these experiments, we injected a single eye of each
animal with therapeutic vector leaving the contralateral unin-
jected eye to serve as an internal control. Injection of a
control vector into the contralateral eye would allow assess-
ment of therapeutic transgene expression in isolation.
However, the main aim of this study was to determine the
overall therapeutic benefit of subretinal injection of an AAV
vector expressing Aipl1.
Interestingly, preservation of photoreceptors in Aipl1 h/h
mice is better than might have been expected given the rela-
tively modest difference in ERG amplitudes between treated
and untreated eyes. This is most likely due to the peculiar
ERG phenotype of the Aipl1 h/h mice. It has previously
been shown that Aipl1 h/h rods have a higher sensitivity to
light compared with normal rod photoreceptor cells, and
require fewer photons to elicit a response (30,31). They mani-
fest supranormal ERG when young, presumably because of a
larger than normal dark current due to higher free cGMP
levels. In this regard, the Aipl1 h/h mice are reminiscent of
rod heterozygotes, which are similarly haploinsufficient for
PDE. The restoration of functional AIPL1 in Aipl1 h/h rods
should, therefore, result in correction of this abnormality so
that photoresponses become more similar to that of wild-type
photoreceptors with a reduction in the altered sensitivity of
Aipl1 h/h rods. Hence, it is likely that the relatively modest
difference in ERGs compared with difference in photoreceptor
preservation seen after treatment is partly due to a reduction in
ERG amplitudes as a result of a reduction in photoreceptor
hypersensitivity following gene transfer.
A number of studies have suggested various roles for AIPL1
in the retina. It was originally suggested that AIPL1 may have
a role in development as a result of its putative interactions
with NUB1 (32), but this is unlikely since both Aipl12/2
and Aipl1 h/h mice have normal retinal architecture prior to
the onset of degeneration (29,30). Biochemical studies using
a yeast two-hybrid screen suggested that AIPL1 may have a
general role in enhancing the protein farnesylation in the
retina. Among retinal proteins known to be farnesylated are
PDE a-subunit, g-transducin and rhodopsin kinase.
However, this hypothesis does not appear to be supported by
the finding that levels of rhodopsin kinase and transducin are
unaffected in Aipl12/2 mice (29). Further assessment of can-
didate retinal proteins in the Aipl12/2 and Aipl1 h/h mice
suggested that cGMP-PDE is the only protein that is reduced
in levels, suggesting that cGMP-PDE is a specific client
protein of AIPL1 (29,30) This study confirms that AIPL1
and cGMP-PDE are intricately linked. We find that
cGMP-PDE, in particular the b-subunit of PDE is mislocalized
to photoreceptor inner segments in untreated Aipl1 h/h eyes
when the animals are examined at 28 weeks following subret-
inal injection in the other eye. In the contralateral treated
eyes of these animals, the b-PDE signal is present in the
photoreceptor outer segments suggesting that AIPL1 could
indeed be a molecular chaperone ensuring PDE translocation
or transport to the outer segments. The fact that photoreceptor
cell loss in the Aipl1 h/h mouse proceeds slowly and outer seg-
ments are present for most of the degeneration makes it poss-
ible to compare and localize b-PDE expression in the outer
segments of treated and untreated eyes. In the Aipl12/2
mouse, the retinal degeneration is too rapid for this analysis
since most of the photoreceptors cells and outer segments
have been lost in the untreated eye by the time AAV8-
mediated expression of Aipl1 commences in the treated eye.
Hence, Aipl1 may protect PDE subunits from proteosomal
degradation or assist in the assembly or folding of the PDE
holoenzyme whereby only properly folded protein is trans-
ported to the outer segments. The exact molecular mechanism
and relationship between AIPL1 and cGMP-PDE remains to
be elucidated. Precise regulation of cGMP synthesis and
cGMP-PDE degradation is critical to the health of photo-
receptors and mutations which disrupt the balance between
the two, result in dysregulation and degeneration of these
cells (33). Mutations in the PDE6B gene encoding the
ß-subunit of cGMP-PDE lead to abnormal increases in
cGMP and subsequent photoreceptor death. Mutations in
retGC1 impair synthesis of cGMP, leading to a state equival-
ent to sustained photo-excitation and photoreceptor cell death
(33–35). Similarly, one of the most important consequences
of mutations in AIPL1 is likely to be the effect on
cGMP-PDE levels, leading to photoreceptor dysfunction and
rapid retinal degeneration.
This study describes the first use of AAV2/8 to treat a murine
model of retinal degeneration. Compared with AAV2/2 and
AAV2/5, AAV2/8 is much more efficient at transducing the
retina (17) (36). This study evaluates the gene replacement
therapy using AAV2/2 and AAV2/8 vectors and finds that the
most effective rescue is achieved using AAV2/8. Superior
results using this vector may result from its higher transduction
efficiency and higher levels of maximal transgene expression.
The Aipl12/2 mouse has a rapid retinal degeneration that is
complete by 3 to 4 weeks of age. Since the onset of AAV2/2
mediated transgene expression occurs between 3 and 4 weeks
following subretinal injection, it is not surprising that we do
not see any evidence of photoreceptor rescue following treat-
ment of Aipl12/2 mice using AAV2/2-CMV-AIPL1. The
first signs of degeneration in the Aipl1 h/h mouse are seen at
12 weeks. By injecting AAV2/2 vectors into 4-week-old
Aipl1 h/h mice, AAV2/2-mediated gene expression will be
expected to commence by 7 to 8 weeks of age and maximal
transgene expression by 16 weeks of age, allowing adequate
time for transgene expression before significant photoreceptor
degeneration occurs. Constant light exposure accelerates the
Aipl1 h/h retinal degeneration by 2–3-fold so that the ONL is
reduced to a single cell layer by 20–21 weeks. For effective
treatment of this animal model, a vector with faster transduction
kinetics is required. The onset of AAV2/8-mediated gene
expression in photoreceptors is known to occur 3–4 days
after subretinal delivery and maximal expression by 7 weeks
(17). Effective rescue of the accelerated model using an
AAV2/8 vector suggests that Aipl12/2 mice may be amenable
to treatment. To ensure adequate transgene expression before
all photoreceptor cells are lost, Aipl12/2 mice are treated
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when they much younger, 12 days old. The potential benefit of
gene transfer has to be balanced against risks of retinal damage
in younger mice. At P12, mice have a fully developed retina and
have opened their eyes, thus facilitating subretinal injection.
AAV2/8-mediated gene expression should occur by P15–16,
at which stage there are still surviving photoreceptors. We
observe photoreceptor rescue with AAV2/8 but not with titre-
matched AAV2/2 in the Aipl12/2 mouse which has very
rapid and severe photoreceptor degeneration. This suggests
that AAV2/8 vector is more efficacious which may be due to
its faster transduction kinetics and higher levels of expression
in photoreceptor cells, properties which have been previously
described (17) (36). However, since a different purification
method was used to produce AAV2/8 vector, we cannot
exclude the possibility that this might in part be responsible
for the higher therapeutic efficacy of this AAV serotype.
In patients, AIPL1 defects are associated with LCA as well as
with cone-rod dystrophy and juvenile retinitis pigmentosa
(27,28). The variability in phenotype may be explained by the
nature of the mutations. To date, 20 disease-causing mutations
in AIPL1 have been reported (HGMD; www.hgmd.org). Of
these, five are likely to lead to complete loss of AIPL1 function;
four are nonsense mutations resulting in a severely truncated
protein and one affects the splice site in intron 2 leading to a
frame shift. The other mutations are missense mutations in
the N-terminal or the tetratricopeptide domains and deletions
in the C-terminal region. In vitro assays have shown that
many of these mutations do not lead to the loss of AIPL1
expression and are unlikely to abolish protein function comple-
tely (32,37,38). It is also likely that there are other variants that
give rise to altered protein with reduced function. In this study,
we have assessed the potential for gene replacement therapy for
AIPL1 deficiency, using mouse models with partial or absent
function and different rates of retinal degeneration. Efficient
rescue of Aipl1 h/h and Aipl12/2 mice suggests that patients
with mutations that do not result in a complete loss of AIPL1
function might respond particularly well to gene replacement
therapy and that treatment may also be effective in LCA
patients with completely absent AILP1 function provided inter-
vention occurs early in life.
MATERIALS AND METHODS
Plasmid constructions and production of recombinant
AAV2 and AAV8
The murine Aipl1 cDNA was PCR amplified from murine
retinal cDNA using primers which have been designed to
encompass the whole of the coding region. The PCR fragment
obtained (1016 bases) was sequenced after cloning into
pGem-T (Promega, Madison, WI, USA). The Aipl1 cDNA
was cloned between the CMV promoter and the SV40 polya-
denylation site of the construct AAV-CMV-GFP (39) to form
the construct pD10/CMV-Aipl1 (total length 5739 bases).
Recombinant AAV2 vector was generated from the murine
construct as described (39). The human AIPL1 cDNA was
also PCR amplified from human retinal DNA using primers
which covered the whole coding region and included part of
the untranslated regions at the 50- and 30-ends. The PCR frag-
ment of 1215 bases was cloned into pGem-T (Promega
Madison, WI, USA) and checked by sequencing. The AIPL1
cDNA was inserted into the parental plasmid AAV-CMV-
GFP, replacing the GFP gene to generate the human construct
pD10/CMV-AIPL1. The plasmids were packaged into AAV2
and AAV8 to generate two pseudotyped AAV viral vectors,
AAV2-CMV-AIPL1 and AAV8-CMV-Aipl1, as described
below.
Recombinant AAV serotype 2 vectors were produced from
the constructs encoding murine Aipl1 and human AIPL1 by a
method described previously, which uses a replicating ampli-
con pHAV7.3 containing the rep and cap genes, and PS1
helper virus (39). The constructs described above and the
pHAV7.3 amplicon were used to transfect BHK cells by incu-
bation with a mixture of three components, peptide6
((K16)GACRRETAWACG) (an integrin-targeting peptide),
plasmid DNA and lipofectin (Invitrogen Ltd., Paisley, UK)
in OptiMEM. BHK cells were transfected with the mixture
containing a total of 60 mg of plasmid DNA for 4 h, and fol-
lowed by incubation with DISC-HSV (PS-1) as helper virus
(39). After 36 h, at completion of the lytic cycle, the cells
were collected, centrifuged and lysed by repeated freeze
thawing. AAV2/2 was purified using a heparin column.
Recombinant AAV serotype 8 vector was produced through
a triple transient transfection method as described previously
(40). The plasmid construct, AAV8 packaging plasmid and
helper plasmid were mixed with 2.5 M calcium chloride and
2X HEPES buffered saline to form transfection complexes
which was then added to 293T cells and left for 72 h. The
cells were harvested, concentrated and lysed to release the
vector. The vector was purified by ion exchange chromato-
graphy. Both of the AAV2/2 and AAV2/8 virus preparations
were concentrated using Centricon 10 columns (Millipore,
Bedford, MA, USA), washed in PBS and concentrated to a
volume of 100–150 ml. Viral particle titres were determined
by comparative dot-blot DNA prepared from purified viral
stocks and defined plasmid controls. Purified vector concen-
trations used for all experiments were 1–2  1012 viral
particles/ml.
Subretinal injection
Subretinal injections were performed on Aipl1 h/h mice at 4
weeks after birth. Surgery was performed under direct ophthal-
moscopic control through an operating microscope. The tip of
a 1.5 cm, 34-gauge hypodermic needle (Hamilton, Switzer-
land) was inserted tangentially through the sclera of the
mouse eye, creating a self-sealing scleral tunnel wound. The
needle tip was brought into focus in the subretinal space and
1.5 ml viral suspension was injected into the subretinal space
to create a bullous retinal detachment around the injection
sites. Two subretinal injections were performed for each
mouse eye, one in the superior hemisphere and one in the
inferior hemisphere. Aipl12/2 mice were injected at P12–
13 days of age.
In vitro assessment of plasmid construct and viral vector
and quantitative PCR
Functional assessment of the construct pD10/CMV-Aipl1
and expression of Aipl1 by AAV-CMV-Aipl1 was assessed
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in vitro. In a 24-well plate, 50 000 293T cells were seeded per
well. One microgram of pD10/CMV-Aipl1 was used to trans-
fect each well along with Lipofectin and peptide6 in the ratio
described above, and 1 ml of AAV-CMV-Aipl1 (1011 vp/mL)
was added to each well. Replicates of 12 were performed
for plasmid transfection and virus infection, respectively.
Transfected cells were collected 24 h later and infected cells
were harvested at 48 h. The cells were lysed and the lysates
pooled together. A standard western blot was performed
using anti-AIPL1 antibody.
Total retinal RNA was isolated from treated and untreated
Aipl1 h/h and from wild-type mice using TRIzol reagent (Invi-
trogen, Paisley, UK). Reverse transcription of RNA into
cDNA was performed by using the Transcriptor First Strand
cDNA Synthesis Kit (Roche Diagnostics, Burgess Hill, UK).
Beta-actin was amplified as an internal standard. PCR
primers for beta-actin quantitative PCR were 50- GGAGG
GGGTTGAGGTGTT and 30- TGTGCACTTTTATTGGTCT
CAAG. Primers for mAIPL1 quantitative PCR were
50-GACGCTGCTGACCTCCAT and 30- GCGGGACAACA
TAGGGTAGA. PCR was carried out for 40 cycles of 958C
(15 s), followed by 608C (60 s).
Immunohistochemistry, morphometric analysis and
immunoblotting
Wild-type eyes, treated and untreated Aipl1 h/h eyes were har-
vested; a cautery mark was placed on the limbus to aid orien-
tation of the eyes, to ensure that quantification of
photoreceptors and immunostaining were performed on equiv-
alent areas on treated and untreated eyes. The eyes were
embedded directly in Optimal Cutting Temperature (OCT)
medium (RA Lamb, E. Sussex, UK), frozen in isopentane
which had been precooled in liquid nitrogen and were stored
at 2808C. Immunofluorescence for AIPL1 and ß-PDE were
performed on freshly cut, frozen retinal sections which had
been serially sectioned at thickness of 9–10 mm. Cryosection
slides were air-dried, post-fixed briefly in 1%PFA and incu-
bated in blocking buffer [10% normal goat serum (Dako
Ltd.), 0.1% Tween and 3% BSA in TBS] for 1 h at room temp-
erature. A polyclonal anti-AIPL1 antibody was diluted 1:500
in blocking buffer and slides were incubated overnight at
48C with the anti-AIPL1 antibody (30). After washes in
TBS, slides were incubated with the secondary antibody,
Alexa Fluorw 488 goat anti-rabbit IgG conjugate (Molecular
Probes, Leiden, The Netherlands) at dilution of 1:150 in
TBS for 2 h. Slides were then washed in TBS before a
second overnight incubation at 48C with ß-PDE antibody pur-
chased from Affinity BioReagents (Neshanic Station, NJ,
USA), diluted at 1:500 in blocking buffer. Following over-
night incubation, slides were washed in TBS and incubated
with quaternary antibody, Alexa Fluorw 546 goat anti-rabbit
IgG conjugate (Molecular Probes, Leiden, The Netherlands)
at dilution of 1:150 in TBS for 2 h. Slides were washed
again in TBS and counterstaining of the nuclei was performed
using Hoechst 33342 diluted at 1:1000. Slides were mounted
in fluorescent mounting medium (Fluormount, Dako) and sec-
tions examined by fluorescent microscopy and images cap-
tured on Leica DC 500 (Zeiss, Germany) digital camera.
For morphometric analysis, retinas were taken at the final
time point of ERG analysis. Cryosections were cut at different
levels through the whole horizontal extension of the retina and
each eye was orientated so that each section spanned over the
superior and inferior retina which are the sites of injection.
Freshly cut, frozen sections at thickness of 10–12 mm were
stained with propidium iodide (PI) to stain photoreceptor
nuclei. To standardize measurements, three sagittally orien-
tated central sections which passed through the optic nerve
head were selected for the analysis. Images were captured
from each side of the optic nerve head in each section, at
approximately midpoint of the distance between the optic
disc and the ora serrata. Sections from matched treated and
untreated eyes were imaged at the same magnification using
confocal microscopy (Zeiss, LSM 510). The nuclei in the
outer nuclear layer in this area were counted by a single
masked observer. The photoreceptor cell count for each eye
was determined by averaging the cell counts from each confo-
cal image of the eye. To control for inter-animal variation in
the rate of degeneration, a paired t-test was performed
between the photoreceptor cell counts in the treated and
untreated eyes of each animal.
For immunoblotting, equal amounts (5–10 mg) of samples
(cell lysates or retinal homogenates) were separated on 9%
SDS–polyacrylamide gel and transferred by electroblotted to
polyvinylidene difluoride membranes (Immobilion-P, Milli-
pore). Membranes were blocked at room temperature for an
hour and incubated overnight with primary antibodies, rabbit
anti-Aipl1 antibody and rabbit ß-PDE antibody (both
described above) and with mouse monoclonal anti-ß-actin
antibody (Sigma) for loading controls at 168C. After
washing, the membranes were then incubated with peroxidase-
conjugated secondary antibodies (goat anti-rabbit IgG and
goat anti-mouse IgG, horseradish peroxidase conjugated anti-
body, Jackson Immunoresearch) for an hour at room tempera-
ture followed by further washes and developed by ECL
substrates (ECL Plus Western Blotting Detection System,
GE Healthcare).
Semithin sections and transmission electron microscopy
Prior to fixation, eyes for semithin sectioning were orientated by
putting a suture on the nasal aspect of the eyes. Eyes were
immersion fixed in 3% glutaraldehyde and 1% paraformalde-
hyde buffered to pH 7.4 with 0.07 M sodium cacodylate-HCL.
After a minimum of 12 h of fixation, the cornea and lens were
removed. The posterior segments were then osmicated for 2 h
with a 1% aqueous solution of osmium tetroxide and dehydrated
through ascending alcohols (50–100%, 10 min per step). After
three changes of 100% ethanol, the specimens were passed
through propylene oxide (2  20 min) and left overnight in a
50:50 mixture of propylene oxide and araldite. Following a
single change to fresh araldite (5 h with rotation), the specimens
were embedded and cured for 24 h at 608C. Using the nasal
suture, the eyes were embedded sagittally so that sectioning
occurred in the vertical plane and the retinal sections contained
the superior and inferior retina. Semithin (0.7 mm) and ultrathin
(0.07 mm) sections were cut using a Leica Ultracut S microtome
fitted with an appropriate diamond knife (Diatome histoknife
Jumbo or Diatome Ultrathin). Following sequential contrasting
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with 1% uranyl acetate and lead citrate, the ultrathin section was
analysed and photographed using a JEOL 1010 Transmission
Electron Microscope operating at 80 kV. Semithin sections
were stained with 1% toluidine blue and evaluated using a
Leitz Diaplan microscope fitted with a Leica digital camera
DC 500 for image capture.
Electroretinographic analysis
Electroretinograms (ERGs) were recorded from both eyes of
Aipl12/2 mice 2 weeks following subretinal injections
(P28) and from Aipl1 h/h mice at 4 weekly intervals follow-
ing subretinal injections. All animals were dark-adapted over-
night (16 h) and anaesthetized with a single intraperitoneal
injection of 0.15 ml of a mixture of Domitor (1 mg/ml medeto-
midine hydrochloride), and ketamine (100 mg/ml), and water in
the ratio 5:3:42 prior to testing. The pupils were dilated using on
drop of Tropicamide 1% and phenylephrine hydrochloride
2.5%. A single drop of 2% hydroxypropylmethylcellulose
was placed on each cornea to keep it moistened and mice
were then placed on a heated platform. ERGs were recorded
using commercially available equipment (Toennies Multiliner
Vision; Jaeger/Toennies, Germany for experiments in Figs 2
and 4; Espion E2; Diagnosys LLC, Massachusetts USA for
experiments in Fig. 5) after corneal contact electrodes and
midline subdermal reference and ground electrodes were
placed. Bandpass filter cut-off frequencies were 1 and
300 Hz. Single flash recordings were obtained at light intensi-
ties increasing from 0.1 to 5000 mcds/m2 presented in a
ganzfeld dome. Ten responses per intensity level were
averaged with an interstimulus interval of 5 s (0.1, 1, 10 and
100 mcds/m2) or five responses per intensity with a 17 s interval
(1000 and 3000 mcds/m2). Dark-adapted, rod dominated
responses were elicited in the dark with 10 ms flashes of white
light (1.37  105 cd/m2) presented at intervals of 1 min. Light-
adapted, cone responses were elicited in the presence of a 41 cd/
m2 rod-desensitizing white background with the same flashes
(1.37  105 cd/m2) presented at intervals of 1 Hz.
Statistical analysis
For ERG analysis, the b-wave amplitude at 1000 mcds/m2 was
used. The b-wave values (a-wave trough b-wave peak) of the
treated (right) eye were paired with the untreated contralateral
(left) eye to provide an internal control. This method controls
for interanimal variance and test–retest variance present in
rodent ERGs. For analysis of the ERG b-wave amplitudes
and photoreceptor cell numbers, paired Student’s t-tests were
used to determine significance (P , 0.05).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
We thank Drs Melanie Sohocki and Michael Dyer for provid-
ing the Aipl12/2 mice. M.H.T. is a Medical Research
Council Clinical Training Fellow.
Conflict of Interest statement. None declared.
FUNDING
H.V.T. is supported by Fonds National Suisse de la Recherche
Scientifique, Roche Research Foundation and Holcim
Stiftung zur Fo¨rderung der wissenschaftlichen Fortbildung.
This work was also supported by grants from the European
Union (AAVEYE), the UK Department of Health, National
Institute of Health Research BMRC for Ophthalmology, NIH
Grant EY10581 and Foundation Fighting Blindness.
REFERENCES
1. Perrault, I., Rozet, J.M., Gerber, S., Ghazi, I., Leowski, C., Ducroq, D.,
Souied, E., Dufier, J.L., Munnich, A. and Kaplan, J. (1999) Leber
congenital amaurosis. Mol. Genet. Metab., 68, 200–208.
2. Schuil, J., Meire, F.M. and Delleman, J.W. (1998) Mental retardation in
amaurosis congenita of Leber. Neuropediatrics, 29, 294–297.
3. Ali, R.R., Sarra, G.M., Stephens, C., Alwis, M.D., Bainbridge, J.W.,
Munro, P.M., Fauser, S., Reichel, M.B., Kinnon, C., Hunt, D.M. et al.
(2000) Restoration of photoreceptor ultrastructure and function in retinal
degeneration slow mice by gene therapy. Nat. Genet., 25, 306–310.
4. Acland, G.M., Aguirre, G.D., Ray, J., Zhang, Q., Aleman, T.S., Cideciyan,
A.V., Pearce-Kelling, S.E., Anand, V., Zeng, Y., Maguire, A.M. et al.
(2001) Gene therapy restores vision in a canine model of childhood
blindness. Nat. Genet., 28, 92–95.
5. Lai, C.M., Yu, M.J., Brankov, M., Barnett, N.L., Zhou, X., Redmond,
T.M., Narfstrom, K. and Rakoczy, P.E. (2004) Recombinant
adeno-associated virus type 2-mediated gene delivery into the Rpe652/2
knockout mouse eye results in limited rescue. Genet. Vaccines Ther., 2, 3.
6. Smith, A.J., Schlichtenbrede, F.C., Tschernutter, M., Bainbridge, J.W.,
Thrasher, A.J. and Ali, R.R. (2003) AAV-mediated gene transfer slows
photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol.
Ther., 8, 188–195.
7. Pawlyk, B.S., Smith, A.J., Buch, P.K., Adamian, M., Hong, D.H.,
Sandberg, M.A., Ali, R.R. and Li, T. (2005) Gene replacement therapy
rescues photoreceptor degeneration in a murine model of Leber congenital
amaurosis lacking RPGRIP. Invest Ophthalmol. Vis. Sci., 46, 3039–3045.
8. Pang, J.J., Chang, B., Kumar, A., Nusinowitz, S., Noorwez, S.M., Li, J.,
Rani, A., Foster, T.C., Chiodo, V.A., Doyle, T. et al. (2006) Gene therapy
restores vision-dependent behavior as well as retinal structure and
function in a mouse model of RPE65 Leber congenital amaurosis. Mol.
Ther., 13, 565–572.
9. Acland, G.M., Aguirre, G.D., Bennett, J., Aleman, T.S., Cideciyan, A.V.,
Bennicelli, J., Dejneka, N.S., Pearce-Kelling, S.E., Maguire, A.M.,
Palczewski, K. et al. (2005) Long-term restoration of rod and cone vision
by single dose rAAV-mediated gene transfer to the retina in a canine
model of childhood blindness. Mol. Ther., 12, 1072–1082.
10. Tschernutter, M., Schlichtenbrede, F.C., Howe, S., Balaggan, K.S.,
Munro, P.M., Bainbridge, J.W., Thrasher, A.J., Smith, A.J. and Ali, R.R.
(2005) Long-term preservation of retinal function in the RCS rat model of
retinitis pigmentosa following lentivirus-mediated gene therapy. Gene
Ther., 12, 694–701.
11. Batten, M.L., Imanishi, Y., Tu, D.C., Doan, T., Zhu, L., Pang, J.,
Glushakova, L., Moise, A.R., Baehr, W., Van Gelder, R.N. et al. (2005)
Pharmacological and rAAV gene therapy rescue of visual functions in a
blind mouse model of Leber congenital amaurosis. PLoS. Med., 2, e333.
12. Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R.,
Balaggan, K., Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N. et
al. (2008) Effect of gene therapy on visual function in Leber’s congenital
amaurosis. N. Engl. J. Med., 358, 2231–2239.
13. Maguire, A.M., Simonelli, F., Pierce, E.A., Pugh, E.N. Jr, Mingozzi, F.,
Bennicelli, J., Banfi, S., Marshall, K.A., Testa, F., Surace, E.M. et al.
(2008) Safety and efficacy of gene transfer for Leber’s congenital
amaurosis. N. Engl. J. Med., 358, 2240–2248.
14. Cideciyan, A.V., Aleman, T.S., Boye, S.L., Schwartz, S.B., Kaushal, S.,
Roman, A.J., Pang, J.J., Sumaroka, A., Windsor, E.A., Wilson, J.M. et al.
(2008) Human gene therapy for RPE65 isomerase deficiency activates the
Human Molecular Genetics, 2009, Vol. 18, No. 12 2113
 at U
CL Library Services on N
ovem
ber 15, 2013
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
retinoid cycle of vision but with slow rod kinetics. Proc. Natl Acad. Sci.
USA, 105, 15112–15117.
15. Ali, R.R., Reichel, M.B., Thrasher, A.J., Levinsky, R.J., Kinnon, C.,
Kanuga, N., Hunt, D.M. and Bhattacharya, S.S. (1996) Gene transfer into
the mouse retina mediated by an adeno-associated viral vector. Hum. Mol.
Genet., 5, 591–594.
16. Rabinowitz, J.E. and Samulski, R.J. (2000) Building a better vector: the
manipulation of AAV virions. Virology, 278, 301–308.
17. Natkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S.E.,
Smith, A.J., Nathwani, A.C. and Ali, R.R. (2007) Assessment of ocular
transduction using single-stranded and self-complementary recombinant
adeno-associated virus serotype 2/8. Gene Ther., 15, 463–467.
18. Schlichtenbrede, F.C., da Cruz, L., Stephens, C., Smith, A.J., Georgiadis,
A., Thrasher, A.J., Bainbridge, J.W., Seeliger, M.W. and Ali, R.R. (2003)
Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following
AAV-mediated gene replacement therapy. J. Gene Med., 5, 757–764.
19. Bennett, J., Tanabe, T., Sun, D., Zeng, Y., Kjeldbye, H., Gouras, P. and
Maguire, A.M. (1996) Photoreceptor cell rescue in retinal degeneration
(rd) mice by in vivo gene therapy. Nat. Med., 2, 649–654.
20. Jomary, C., Vincent, K.A., Grist, J., Neal, M.J. and Jones, S.E. (1997)
Rescue of photoreceptor function by AAV-mediated gene transfer in a
mouse model of inherited retinal degeneration. Gene Ther., 4, 683–690.
21. Takahashi, M., Miyoshi, H., Verma, I.M. and Gage, F.H. (1999) Rescue
from photoreceptor degeneration in the rd mouse by human
immunodeficiency virus vector-mediated gene transfer. J. Virol., 73,
7812–7816.
22. Kumar-Singh, R. and Farber, D.B. (1998) Encapsidated adenovirus
mini-chromosome-mediated delivery of genes to the retina: application
to the rescue of photoreceptor degeneration. Hum. Mol. Genet., 7,
1893–1900.
23. Pang, J.J., Boye, S.L., Kumar, A., Dinculescu, A., Deng, W., Li, J., Li, Q.,
Rani, A., Foster, T.C., Chang, B. et al. (2008) AAV-mediated gene
therapy for retinal degeneration in the rd10 mouse containing a recessive
PDEbeta mutation. Invest Ophthalmol. Vis. Sci., 49, 4278–4283.
24. Van der, S.J., Chapple, J.P., Clark, B.J., Luthert, P.J., Sethi, C.S. and
Cheetham, M.E. (2002) The Leber congenital amaurosis gene product
AIPL1 is localized exclusively in rod photoreceptors of the adult human
retina. Hum. Mol. Genet., 11, 823–831.
25. Chapple, J.P., Grayson, C., Hardcastle, A.J., Saliba, R.S., Van der Spuy, J.
and Cheetham, M.E. (2001) Unfolding retinal dystrophies: a role for
molecular chaperones? Trends Mol. Med., 7, 414–421.
26. Petrulis, J.R. and Perdew, G.H. (2002) The role of chaperone proteins in
the aryl hydrocarbon receptor core complex. Chem. Biol. Interact., 141,
25–40.
27. Sohocki, M.M., Perrault, I., Leroy, B.P., Payne, A.M., Dharmaraj, S.,
Bhattacharya, S.S., Kaplan, J., Maumenee, I.H., Koenekoop, R., Meire,
F.M. et al. (2000) Prevalence of AIPL1 mutations in inherited retinal
degenerative disease. Mol. Genet. Metab., 70, 142–150.
28. Dharmaraj, S., Leroy, B.P., Sohocki, M.M., Koenekoop, R.K., Perrault, I.,
Anwar, K., Khaliq, S., Devi, R.S., Birch, D.G., De Pool, E. et al. (2004)
The phenotype of Leber congenital amaurosis in patients with AIPL1
mutations. Arch. Ophthalmol., 122, 1029–1037.
29. Ramamurthy, V., Niemi, G.A., Reh, T.A. and Hurley, J.B. (2004) Leber
congenital amaurosis linked to AIPL1: a mouse model reveals
destabilization of cGMP phosphodiesterase. Proc. Natl Acad. Sci. USA,
101, 13897–13902.
30. Liu, X., Bulgakov, O.V., Wen, X.H., Woodruff, M.L., Pawlyk, B., Yang,
J., Fain, G.L., Sandberg, M.A., Makino, C.L. and Li, T. (2004) AIPL1, the
protein that is defective in Leber congenital amaurosis, is essential for the
biosynthesis of retinal rod cGMP phosphodiesterase. Proc. Natl Acad. Sci.
USA, 101, 13903–13908.
31. Makino, C.L., Wen, X.H., Michaud, N., Peshenko, I.V., Pawlyk, B.,
Brush, R.S., Soloviev, M., Liu, X., Woodruff, M.L., Calvert, P.D. et al.
(2006) Effects of low AIPL1 expression on phototransduction in rods.
Invest Ophthalmol. Vis. Sci., 47, 2185–2194.
32. Akey, D.T., Zhu, X., Dyer, M., Li, A., Sorensen, A., Blackshaw, S.,
Fukuda-Kamitani, T., Daiger, S.P., Craft, C.M., Kamitani, T. and Sohocki,
M.M. (2002) The inherited blindness associated protein AIPL1 interacts
with the cell cycle regulator protein NUB1. Hum. Mol. Genet., 11, 2723–
2733.
33. Farber, D.B. (1995) From mice to men: the cyclic GMP phosphodiesterase
gene in vision and disease. The Proctor Lecture. Invest Ophthalmol. Vis.
Sci., 36, 263–275.
34. Semple-Rowland, S.L., Lee, N.R., Van Hooser, J.P., Palczewski, K. and
Baehr, W. (1998) A null mutation in the photoreceptor guanylate cyclase
gene causes the retinal degeneration chicken phenotype. Proc. Natl. Acad.
Sci. USA, 95, 1271–1276.
35. Perrault, I., Rozet, J.M., Calvas, P., Gerber, S., Camuzat, A., Dollfus, H.,
Chatelin, S., Souied, E., Ghazi, I., Leowski, C. et al. (1996)
Retinal-specific guanylate cyclase gene mutations in Leber’s congenital
amaurosis. Nat. Genet., 14, 461–464.
36. Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C.,
Petrillo, M., Vandenberghe, L.H., Wilson, J.M., Marigo, V., Surace, E.M.
and Auricchio, A. (2007) Novel adeno-associated virus serotypes
efficiently transduce murine photoreceptors. J. Virol., 81, 11372–11380.
37. Ramamurthy, V., Roberts, M., van den Akker, F., Niemi, G., Reh, T.A.
and Hurley, J.B. (2003) AIPL1, a protein implicated in Leber’s congenital
amaurosis, interacts with and aids in processing of farnesylated proteins.
Proc. Natl Acad. Sci. USA, 100, 12630–12635.
38. Van der Spuy, J. and Cheetham, M.E. (2004) The Leber congenital
amaurosis protein AIPL1 modulates the nuclear translocation of NUB1
and suppresses inclusion formation by NUB1 fragments. J. Biol. Chem.,
279, 48038–48047.
39. Zhang, X., De Alwis, M., Hart, S.L., Fitzke, F.W., Inglis, S.C., Boursnell,
M.E., Levinsky, R.J., Kinnon, C., Ali, R.R. and Thrasher, A.J. (1999)
High-titer recombinant adeno-associated virus production from replicating
amplicons and herpes vectors deleted for glycoprotein H. Hum. Gene
Ther., 10, 2527–2537.
40. Nathwani, A.C., Gray, J.T., McIntosh, J., Ng, C.Y., Zhou, J., Spence, Y.,
Cochrane, M., Gray, E., Tuddenham, E.G. and Davidoff, A.M. (2007)
Safe and efficient transduction of the liver after peripheral vein infusion of
self-complementary AAV vector results in stable therapeutic expression
of human FIX in nonhuman primates. Blood, 109, 1414–1421.
2114 Human Molecular Genetics, 2009, Vol. 18, No. 12
 at U
CL Library Services on N
ovem
ber 15, 2013
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
